BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
DTSTART:20210328T030000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:CEST
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20211031T020000
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:CET
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20260405T232516Z
UID:1617804000@ist.ac.at
DTSTART:20210407T160000
DTEND:20210407T170000
DESCRIPTION:Speaker: Alexander Belcredi and Lorenzo Corsini\nhosted by Alex
 ander Schwartz\nAbstract: AbstractIn 2017 we started building our biotech 
 company\, PhagoMed\, with a big vision: to revolutionize anti-bacterials a
 nd move us from broad-spectrum antibiotics to narrow-spectrum therapies. F
 our years later we’ve come a long way. We successfully built a strong te
 am\, established our own lab and science\, filed our own patents and raise
 d substantial funds. Along the way we celebrated many successes and learne
 d from our failures. Reflecting on the journey so far\, we can share a num
 ber of experiences around finding an idea for a new company\, how to get i
 t going and what to do / not to do. CVAlexander Belcredi has been working
  in the pharmaceutical space for over a decade. He spent nine years at the
  Boston Consulting Group (BCG) where he was part of the global Healthcare 
 team\, focusing on Pharma and Medtech. While at BCG\, Alexander became acu
 tely aware of the urgent need to develop alternatives to antibiotics and w
 as fascinated by the role that phage therapy can play. In 2017\, he co-fou
 nded PhagoMed Biopharma GmbH\, a biotech company developing phage-based ph
 armaceuticals to treat bacterial infections. At PhagoMed he serves as a CE
 O and focuses on the Business & Finance responsibilities. Alexander holds 
 an MA in Modern History and Economics from the University of St. Andrews a
 s well as an MBA from INSEAD. Lorenzo has long been fascinated by the man
 y examples of lysins effectively treating bacterial infections. And by how
  under-exploited this extremely diverse and abundant natural resource is. 
 Lorenzo spent the last 9 years at the Boston Consulting Group (BCG) and wa
 s a Senior Principal in his latest role. Lorenzo has advised the top Bioph
 armaceutical companies\, on how to improve their quality and efficiency of
  production. Earlier in his career he worked at Sanofi Aventis in lead opt
 imization after high-throughput screening. Lorenzo co-founded PhagoMed in 
 2017 and currently serves as CEO with a focus on the Research & Developmen
 t responsibilities. Lorenzo studied biochemistry at Frankfurt University a
 nd holds a PhD from the European Molecular Biology Laboratory (EMBL) in He
 idelberg. 
LOCATION:Online\, ISTA
ORGANIZER:isabella.riedler@ist.ac.at
SUMMARY:Alexander Belcredi and Lorenzo Corsini: [Online] TWIST Talk by Alex
 ander Belcredi and Lorenzo Corsini of PhagoMed
URL:https://talks-calendar.ista.ac.at/events/3150
END:VEVENT
END:VCALENDAR